Home>Topics>>NPS Pharma Drifts Higher On Potential Orphan Drug Approval
NPS Pharma Drifts Higher On Potential Orphan Drug Approval
Long Investing Ideas from Seeking Alpha
Tue, 4 Dec 2012
By Brian L. Wilson : NPS Pharmaceuticals (NASDAQ: NPSP ) is one of the many biotechstocks that has given its shareholders exceptionally large returns this year. The Utah-based company has a diverse pipeline that contains five compounds, targeting four different indications. NPS' flagship product ...
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.